2022
DOI: 10.1038/s41398-022-02203-6
|View full text |Cite
|
Sign up to set email alerts
|

Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians’ attitudes to sociocultural differences between patients across the globe

Abstract: Genetic testing has evolved rapidly over recent years and new developments have the potential to provide insights that could improve the ability to diagnose, treat, and prevent diseases. Information obtained through genetic testing has proven useful in other specialties, such as cardiology and oncology. Nonetheless, a range of barriers impedes techniques, such as whole-exome or whole-genome sequencing, pharmacogenomics, and polygenic risk scoring, from being implemented in psychiatric practice. These barriers … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
21
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 19 publications
(21 citation statements)
references
References 164 publications
0
21
0
Order By: Relevance
“…Use of the Genetic Counselling Outcome Scale (GCOS-24), which is a Patient Reported Outcome Measure (PROM), has been advocated to help provide evidence to support service development in genetic counselling. This measure was developed for use in the National Health Service (NHS) system of healthcare in The United Kingdom and has since been validated across other countries like Denmark and The Netherlands ( 22–24 ). The other factor to consider is what patients and parents may find useful to know in the clinical context.…”
Section: Discussionmentioning
confidence: 99%
“…Use of the Genetic Counselling Outcome Scale (GCOS-24), which is a Patient Reported Outcome Measure (PROM), has been advocated to help provide evidence to support service development in genetic counselling. This measure was developed for use in the National Health Service (NHS) system of healthcare in The United Kingdom and has since been validated across other countries like Denmark and The Netherlands ( 22–24 ). The other factor to consider is what patients and parents may find useful to know in the clinical context.…”
Section: Discussionmentioning
confidence: 99%
“…Also, sensitive information may fall into the wrong hands, such as insurance companies ( De Denus et al, 2013 ; Frigon et al, 2019 ). Therefore, education, counselling and robust policies become crucial to empower and protect patients as well as HCPs ( Hayashi et al, 2022 ; Pinzón-Espinosa et al, 2022 ). The Genetic Non-Discrimination Act (GNA) makes it a criminal offence for a service provider or anyone entering into a contract with a person to require or compel that person to take or disclose the results of, a genetic test ( Branch, 2017 ).…”
Section: Previously Raised Challenges and Efficient Solutionsmentioning
confidence: 99%
“…Whilst the research on PGx-guided treatment is promising, implementing patient-specific genetic testing to guide antidepressant prescription into clinical practice does not come without its challenges ( Gurwitz and Motulsky, 2007 ; Pinzón-Espinosa et al, 2022 ). Precision medicine, or the individualised and tailored approach to medical treatment, has been made a government funding priority across the world, with countries such as the United States, Canada, the United Kingdom, and China making significant headway in their commitments to implementation over the last 5 years 9 , 10 , 11 .…”
Section: Clinical Application Of Pharmacogenetics In Youth Mental Healthmentioning
confidence: 99%